Shares surged as Precipio Diagnostics, a tiny cancer-testing firm, posted the strongest quarter in its history — forcing investors to weigh accelerating growth against a balance sheet that auditors have flagged as fragile.
PRPO jumped 11.6% to $27.55 on August 19, extending a five-day rally of over 22% from its August 12 close of $22.54. The catalyst: Precipio reported quarterly revenue above $7 million for the first time in its history, alongside a return to positive adjusted EBITDA and positive operating cash flow.
• The Numbers Are Small but Moving Fast
Revenue hit $7.0M, up 22% year over year from $5.7M in Q2-2025, composed of $6.1M in pathology (diagnostic-services) revenue and $0.9M in product revenue — the latter up from $0.66M last quarter.
Gross margin stood at roughly 45%, with product revenue growing 45% and diagnostic case volume up 26%. For a company with roughly 1.79 million shares outstanding and a market cap near $42–50 million , each incremental revenue dollar moves the valuation math meaningfully.
• Turning Cash-Flow Positive Changes the Survival Calculus
Operating cash flow was $700,000 in Q2, lifting the cash balance past $3 million — nearly triple the $1.1M a year earlier. CEO Ilan Danieli emphasized that "We've achieved this level of cash without a financing event." That matters because Precipio's prior 10-Q explicitly stated "substantial doubt about the company's ability to continue as a going concern" without additional revenue growth or financing. Sustaining positive cash flow is the clearest path to removing that warning, which currently caps the stock's appeal to institutional buyers.
• The Pipeline Looks Promising — But Scale Remains Tiny
Precipio added roughly 10 new distributor reps in Q2 and identified more than 25 new qualified customers, with over 30 customer meetings scheduled or completed.
Management targets a $500 million addressable market in blood-cancer diagnostics. Yet annualized revenue of ~$28M means Precipio still captures well under 6% of that market — leaving enormous room to grow but also enormous room for better-capitalized rivals to dominate.
• The Valuation Question Ahead At $27.55, PRPO trades at roughly 1.7× annualized sales — modest for healthcare growth but rich for a company still reporting GAAP net losses. If H2 sustains the Q2 trajectory, full-year revenue could approach $30 million, potentially justifying a premium. The real inflection will be whether Precipio can shed its going-concern label, which would open the door to wider institutional ownership and lower financing costs.